# CDMO

Type: Technology

Source: GetYourBrief — https://getyourbrief.com/entity/cdmo
Canonical HTML page: https://getyourbrief.com/entity/cdmo

## Recent coverage (2 stories, network-wide)

### Agilent Q1 2026: Pharma Resilience Battles Academic Funding Headwinds
2026-02-26 00:37:40 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Agilent reported a 4.4% core revenue growth in Q1 2026, driven by a strong 7% uptick in the pharmaceutical sector despite an 8% decline in academic and government markets. The company is navigating margin pressures from new tariffs while leaning into high-growth areas like GLP-1 manufacturing and CDMO services.
Full story: https://getbiobrief.com/story/agilent-q1-2026-earnings-pharma-vs-academia

### Agilent Navigates Tariff Headwinds and Academic Softness in Q1 2026
2026-02-26 00:37:03 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Agilent Technologies reported a resilient Q1 2026 with $1.8 billion in revenue, driven by a 7% growth in the pharma sector despite significant headwinds in academic and government funding. While the company faced a 100-basis-point gross margin compression due to rising tariffs and weather disruptions, strong performance in the Agilent CrossLab Group suggests a shift toward service-oriented recurring revenue.
Full story: https://gethealthbrief.com/story/agilent-q1-2026-earnings-analysis-healthcare-it

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.